• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Zevra Therapeutics, Inc. - Common Stock (NQ: ZVRA )

    7.120 +0.270 (+3.94%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 2, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 819,309
    Open 6.810
    Bid (Size) 7.010 (30)
    Ask (Size) 7.880 (1)
    Prev. Close 6.850
    Today's Range 6.777 - 7.410
    52wk Range 3.890 - 8.950
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Beyond The Numbers: 7 Analysts Discuss Zevra Therapeutics Stock
    Via Benzinga
    Zevra Therapeutics' Drug Becomes First FDA-Approved Treatment For Ultra-Rare Neurodegenerative Disease
    The FDA has approved Zevra Therapeutics' Miplyffa (arimoclomol) as the first treatment for neurological symptoms of Neimann-Pick disease, type C. This approval follows favorable voting by the Genetic... 
    Via Benzinga
    Exposures Product Safety

    Performance

    YTD
    +4.25%
    +4.25%
    1 Month
    -2.47%
    -2.47%
    3 Month
    +65.39%
    +65.39%
    6 Month
    +41.55%
    +41.55%
    1 Year
    +54.78%
    +54.78%

    More News

    Read More
    Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    Zevra Therapeutics Mixed Q2 Results: Details
    Via Benzinga
    Zevra Therapeutics: Q4 Earnings Insights
    Via Benzinga
    Earnings Outlook For Zevra Therapeutics
    Via Benzinga
    ZVRA Stock Earnings: Zevra Therapeutics Misses EPS, Beats Revenue for Q2 2024
    Via InvestorPlace
    PubMatic, Eventbrite, Five9 And Other Big Stocks Moving Lower In Friday's Pre-Market Session
    Via Benzinga
    Why Kellanova Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    FDA Panel Backs Zevra's Arimoclomol For Rare Genetic Disorder, Analyst Highlights Balanced Portfolio Of Marketed Products And Pipeline Assets Focused On Rare Diseases
    Via Benzinga
    Exposures Product Safety
    10 Health Care Stocks Whale Activity In Today's Session
    Via Benzinga
    Insiders Buying Zevra Therapeutics And 1 Other Stock
    Via Benzinga
    Insiders Buying Barnes & Noble Education And 2 Other Stocks
    Via Benzinga
    SmallCap Tech/Biotech Stocks July/Aug 2024: ZVSA, DYAI, ZVRA, PRSO, RLMD, VTAK, ENTO, INBS, KAVL
    Via AB Newswire
    FDA Convenes Expert Panel Meeting For Zevra Therapeutics' Arimoclomol, Analyst Optimistic About Approval Despite Small Patient Base
    Via Benzinga
    Exposures Product Safety
    ZVRA Stock Earnings: Zevra Therapeutics Beats EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    Zevra Therapeutics, Inc. (NASDAQ: ZVRA) Letter to Stakeholders Looks Like Launch Code to Drive Value
    Via Investor Brand Network
    ZEVRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Zevra Therapeutics, Inc. on Behalf of Zevra Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Zevra Therapeutics, Inc. (ZVRA)
    From Kirby McInerney LLP
    Via GlobeNewswire
    ZVRA Stock Earnings: Zevra Therapeutics Misses EPS, Beats Revenue for Q4 2023
    Via InvestorPlace
    Earnings Scheduled For March 28, 2024
    Via Benzinga
    Microsoft To Rally Over 20%? Here Are 10 Top Analyst Forecasts For Thursday
    Via Benzinga
    BioMedNewsBreaks – Zevra Therapeutics Inc. (NASDAQ: ZVRA) Resubmits Arimoclomol New Drug Application to the FDA
    Via Investor Brand Network
    Exposures Product Safety
    Earnings Scheduled For November 7, 2023
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.